Anika Gross Profit from 2010 to 2024

ANIK Stock

USD 17.20 0.23 1.36%

Anika Therapeutics Gross Profit yearly trend continues to be quite stable with very little volatility. Gross Profit may rise above about 108.2 M this year. Gross Profit is the profit Anika Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1993-03-31

Previous Quarter

27.4 M

Current Value

1.4 M

Quarterly Volatility

8.9 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.3 M or Selling General Administrative of 103.5 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.

Check out the analysis of Anika Therapeutics Correlation against competitors.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Anika Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Anika Therapeutics minus its cost of goods sold. It is profit before Anika Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Anika Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 96.78 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Anika Gross Profit Regression Statistics

	Arithmetic Mean	71,467,497
	Geometric Mean	50,915,847
	Coefficient Of Variation	39.30
	Mean Deviation	20,710,794
	Median	79,352,000
	Standard Deviation	28,083,885
	Sample Variance	788.7T
	Range	107.9M
	R-Value	0.85
	Mean Square Error	230.8T
	R-Squared	0.73
	Significance	0.000052
	Slope	5,359,059
	Total Sum of Squares	11041.9T

Anika Gross Profit History

	2024	108.2 M
	2023	103.1 M
	2022	93.6 M
	2021	82.9 M
	2020	69 M
	2019	85.9 M
	2018	74.3 M

Other Fundumenentals of Anika Therapeutics

Gross Profit Margin

Anika Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Accumulated Depreciation	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.6	0.95	0.51	0.6	0.58	0.89	0.27	0.41	0.68	0.86	0.64	0.42	0.6	0.76	0.16	-0.12	-0.08	-0.66	0.36	-0.34	-0.04
Total Stockholder Equity	0.98		-0.72	0.98	0.42	0.56	0.42	0.95	0.14	0.49	0.7	0.87	0.64	0.4	0.47	0.81	0.2	-0.13	-0.17	-0.71	0.38	-0.21	-0.09
Net Debt	-0.6	-0.72		-0.71	-0.01	-0.18	0.12	-0.85	0.44	-0.25	-0.63	-0.61	-0.45	-0.34	0.06	-0.63	-0.27	0.13	0.32	0.68	-0.34	-0.35	0.25
Retained Earnings	0.95	0.98	-0.71		0.36	0.46	0.39	0.93	0.15	0.51	0.56	0.81	0.72	0.27	0.47	0.79	0.23	-0.28	-0.11	-0.65	0.44	-0.16	-0.1
Accounts Payable	0.51	0.42	-0.01	0.36		0.75	0.77	0.33	0.56	0.38	0.4	0.43	0.17	0.22	0.41	0.46	-0.54	0.01	0.18	-0.22	-0.33	-0.8	0.61
Net Receivables	0.6	0.56	-0.18	0.46	0.75		0.65	0.48	0.44	0.49	0.69	0.67	0.11	0.52	0.28	0.7	-0.56	-0.01	-0.2	-0.53	-0.33	-0.67	0.63
Total Liab	0.58	0.42	0.12	0.39	0.77	0.65		0.24	0.67	0.08	0.32	0.39	0.31	0.32	0.71	0.32	-0.35	-0.17	0.28	-0.2	-0.07	-0.79	0.46
Total Current Assets	0.89	0.95	-0.85	0.93	0.33	0.48	0.24		-0.01	0.52	0.71	0.87	0.59	0.38	0.2	0.86	0.16	-0.19	-0.26	-0.71	0.27	-0.01	-0.12
Short Term Debt	0.27	0.14	0.44	0.15	0.56	0.44	0.67	-0.01		0.26	-0.08	0.23	0.32	0.02	0.4	0.2	-0.34	-0.19	0.25	0.19	-0.16	-0.64	0.41
Short Term Investments	0.41	0.49	-0.25	0.51	0.38	0.49	0.08	0.52	0.26		0.25	0.47	0.32	-0.03	-0.1	0.71	-0.35	-0.33	-0.19	-0.29	-0.22	-0.27	0.38
Common Stock	0.68	0.7	-0.63	0.56	0.4	0.69	0.32	0.71	-0.08	0.25		0.79	0.18	0.84	0.2	0.62	-0.05	0.21	-0.38	-0.75	0.0	-0.16	0.06
Property Plant Equipment	0.86	0.87	-0.61	0.81	0.43	0.67	0.39	0.87	0.23	0.47	0.79		0.53	0.59	0.27	0.79	0.05	-0.15	-0.27	-0.61	0.08	-0.2	-0.04
Current Deferred Revenue	0.64	0.64	-0.45	0.72	0.17	0.11	0.31	0.59	0.32	0.32	0.18	0.53		0.19	0.41	0.47	0.23	-0.53	0.03	-0.3	0.42	-0.04	-0.16
Good Will	0.42	0.4	-0.34	0.27	0.22	0.52	0.32	0.38	0.02	-0.03	0.84	0.59	0.19		0.2	0.32	-0.05	0.12	-0.44	-0.56	-0.02	-0.07	0.05
Intangible Assets	0.6	0.47	0.06	0.47	0.41	0.28	0.71	0.2	0.4	-0.1	0.2	0.27	0.41	0.2		0.04	0.27	0.09	0.32	-0.25	0.5	-0.56	-0.05
Net Tangible Assets	0.76	0.81	-0.63	0.79	0.46	0.7	0.32	0.86	0.2	0.71	0.62	0.79	0.47	0.32	0.04		-0.25	-0.26	-0.44	-0.72	-0.07	-0.23	0.28
Long Term Debt Total	0.16	0.2	-0.27	0.23	-0.54	-0.56	-0.35	0.16	-0.34	-0.35	-0.05	0.05	0.23	-0.05	0.27	-0.25		0.25	-0.02	-0.04	0.84	0.57	-0.95
Capital Surpluse	-0.12	-0.13	0.13	-0.28	0.01	-0.01	-0.17	-0.19	-0.19	-0.33	0.21	-0.15	-0.53	0.12	0.09	-0.26	0.25		-0.18	-0.12	0.04	-0.04	-0.25
Deferred Long Term Liab	-0.08	-0.17	0.32	-0.11	0.18	-0.2	0.28	-0.26	0.25	-0.19	-0.38	-0.27	0.03	-0.44	0.32	-0.44	-0.02	-0.18		0.6	0.01	-0.33	0.05
Accumulated Depreciation	-0.66	-0.71	0.68	-0.65	-0.22	-0.53	-0.2	-0.71	0.19	-0.29	-0.75	-0.61	-0.3	-0.56	-0.25	-0.72	-0.04	-0.12	0.6		-0.18	0.1	-0.03
Net Invested Capital	0.36	0.38	-0.34	0.44	-0.33	-0.33	-0.07	0.27	-0.16	-0.22	0.0	0.08	0.42	-0.02	0.5	-0.07	0.84	0.04	0.01	-0.18		0.38	-0.65
Net Working Capital	-0.34	-0.21	-0.35	-0.16	-0.8	-0.67	-0.79	-0.01	-0.64	-0.27	-0.16	-0.2	-0.04	-0.07	-0.56	-0.23	0.57	-0.04	-0.33	0.1	0.38		-0.65
Capital Stock	-0.04	-0.09	0.25	-0.1	0.61	0.63	0.46	-0.12	0.41	0.38	0.06	-0.04	-0.16	0.05	-0.05	0.28	-0.95	-0.25	0.05	-0.03	-0.65	-0.65

Click cells to compare fundamentals

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Gross Profit, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	103.1 M	108.2 M
Gross Profit Margin	0.62	0.45

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:

How To Invest In Anika

Details

Is Anika Stock a good investment?

Details

What is Anika Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Anika Therapeutics Correlation against competitors.

For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.51)

Earnings Share

(6.73)

Revenue Per Share

11.139

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.04)

The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anika Gross Profit from 2010 to 2024

Latest Anika Therapeutics' Gross Profit Growth Pattern

Anika Gross Profit Regression Statistics

Anika Gross Profit History

Other Fundumenentals of Anika Therapeutics

Anika Therapeutics Gross Profit component correlations

About Anika Therapeutics Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY